Millions of People Will Be Blindsided in 2023. Will You Be One of Them?

On December 13, Louis Navellier, Eric Fry & Luke Lango will reveal the major events that could rock the markets in 2023. Will your money be safe?

Tue, December 13 at 4:00PM ET

BIOR Stock Starts Trading as Progenity’s Rebrand Takes Shape. What to Know.

A longtime favorite of many retail investors, biotech company Progenity has changed its name to Biora Therapeutics (NASDAQ:BIOR). Today the company has officially begun trading under the name Biora and the symbol BIOR. Additionally, the company will report its first-quarter results today after the market closes.

Packs of blue and pink pills are piled on top of each other.
Source: Shutterstock

In conjunction with its name change, Biora is embracing a new strategy. More specifically, the company has decided to “focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.”

Also known as biologicals, biotherapeutics “are drug therapy products where the active substance is extracted or produced from a biological source.” The U.S. Food and Drug Administration has approved biotherapeutics including “therapeutic proteins … monoclonal antibodies … and vaccines.”

What to Know About BIOR Stock

Biora is developing “smart pills” that can deliver biologics directly “to the [gastrointestinal] tract.” It’s also looking to enable “systemic, needle-free delivery of biotherapeutics.”

The company has created a capsule that it says “is designed to autonomously identify specific locations in the GI tract and release a therapeutic dose.” Using this method is supposed to create fewer, less-intense side effects, Biora explains.

In a Jan. 3 column, InvestorPlace analyst Louis Navellier wrote that BIOR stock was “cheap and could possibly double or more.” Navellier was upbeat on the company’s decision to focus on its biotherapeutics projects.

On the date of publication, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.

Article printed from InvestorPlace Media,

©2022 InvestorPlace Media, LLC